Emily D. Schultz

Emily D. Schultz

Interventional Cardiology | Cardiology
130 East 77th Street, Black Hall
9th Floor
New York, NY 10075

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Differences Between STEMI and NSTEMI Complicated by Cardiogenic Shock: Insights From a Contemporary Multilevel Registry.

Differences Between STEMI and NSTEMI Complicated by Cardiogenic Shock: Insights From a Contemporary Multilevel Registry.

Journal: JACC. Advances
Published: April 23, 2026

Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study.

Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study.

Journal: JCO precision oncology
Published: April 16, 2026

Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors.

Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors.

Journal: JCO precision oncology
Published: January 23, 2026

Pancreatic adenocarcinoma in a patient with a germline RB1 pathogenic variant.

Pancreatic adenocarcinoma in a patient with a germline RB1 pathogenic variant.

Journal: Familial cancer
Published: February 16, 2025

Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer.

Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer.

Journal: NPJ breast cancer
Published: February 07, 2025

Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer.

Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer.

Journal: Oncogene
Published: August 13, 2024

Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy.

Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy.

Journal: Cancers
Published: March 21, 2024

Safety of Retrograde Tibial-Pedal Access and Intervention in Patients with Single Remaining Non-Occluded Infra-Popliteal Runoff Artery.

Safety of Retrograde Tibial-Pedal Access and Intervention in Patients with Single Remaining Non-Occluded Infra-Popliteal Runoff Artery.

Journal: Journal of cardiovascular development and disease
Published: September 28, 2023

Determinants of response to CDK4/6 inhibitors in the real-world setting.

Determinants of response to CDK4/6 inhibitors in the real-world setting.

Journal: NPJ precision oncology
Published: March 14, 2023

Whole-Genome Sequencing Identifies PPARGC1A as a Putative Modifier of Cancer Risk in BRCA1/2 Mutation Carriers.

Whole-Genome Sequencing Identifies PPARGC1A as a Putative Modifier of Cancer Risk in BRCA1/2 Mutation Carriers.

Journal: Cancers
Published: March 18, 2022

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center.

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center.

Journal: The oncologist
Published: October 05, 2021

UACA locus is associated with breast cancer chemoresistance and survival.

UACA locus is associated with breast cancer chemoresistance and survival.

Journal: NPJ breast cancer
Published: September 29, 2021
Showing 1-12 of 14

Last Updated: 09/26/2026